~~<i id='C6B5048E70'><strike id='C6B5048E70'><tt id='C6B5048E70'><pre id='C6B5048E70'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：explore 2025-09-30 05:33:43 Page View：89416

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Readout LOUD podcast: ASCO preview, a Duchenne trial failure
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Woman returns to dialysis after doctors remove transplanted pig kidney

LisaPisanolooksatphotosofherdogafterhersurgeriesatNYULangoneHealthinNewYorkonApril22.Doctorshadtorem

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Focused ultrasound for uterine fibroids: an uphill battle

courtesyFocusedUltrasoundFoundationIfaneffectivetreatmentisavailableforonecommondiseaseinmen,andthat